Specifically, we tested CpHV-1 with abemaciclib (for HR+/HER2− BC) (7), tucatinib (for advanced HER2+ BC) (8), and inavolisib (under clinical evaluation for TNBC) (9). The gene discussed is HR; the disease is breast cancer.